

ONGOING CLINICAL TRIALS (ACTIVE RECRUITMENT)

No.	Protocol ID	Study Title	Investigator(s)
1	OXFORD	Validation of Chromosomal Conformation Signatures in patients undergoing Cancer Immunotherapy (only involving blood withdrawal at 2 or more time points: at 0(treatment naïve) , 9th week (3rd cycle) and 18th week (6th cycle)	Dr Hayani binti Abdul Wahid <i>(eligible patients from other oncologists are also encouraged to donate blood for this trial. The participation as donor will not alter the standard of care from primary physician)</i>
2	JIMMY MEL	A PK study to compare GME751 (proposed pembrolizumab biosimilar) and US-licensed and EU-authorized Keytruda® in participants with Stage II and III Melanoma in the adjuvant setting	Dr Sanjeev Chandra Joshi / Dr Hayani binti Abdul Wahid
3	ELEGANT	Elacestrant versus Standard Endocrine Therapy in Women and Men with Node-positive, ER+, HER2- Early Breast Cancer with High Risk of Recurrence - A Global, Multicenter, Randomized, Open-label Phase 3 Study	Dr Sanjeev Chandra Joshi / Dr Hayani binti Abdul Wahid

ONGOING CLINICAL TRIALS (NO LONGER RECRUITING)

No.	Protocol ID	Study Title	Investigator(s)
1	CAMBRIA-1	A Study of Camizestrant in ER+/HER2- Early Breast Cancer after at least 2 years of Standard Adjuvant Endocrine-Based Therapy	Dr Sanjeev Chandra Joshi / Dr Hayani binti Abdul Wahid
2	JIMMY LUNG	A study to compare efficacy, safety, and immunogenicity of GME751 and EU-authorized Keytruda in adult participants with untreated Metastatic Non-Squamous Non-Small Cell Lung	Dr Sanjeev Chandra Joshi / Dr Hayani binti Abdul Wahid